Security
SL Science Holding Limited Ordinary Shares · SLBT
SLBTNASDAQCommon stockCurrentCIK 2070534Updated Nov 22, 2026
SLBT price & chart
Loading TradingView…
NASDAQ:SLBT on TradingView ↗About the company
SL Science Holding Limited is a biomedical company specializing in developing innovative cellular and gene therapies. Established with a commitment to advancing regenerative medicine and cancer treatment, the Company hopes to utilize immune cell technologies to target cancer, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Gamma Delta T cells targeting solid tumor indications including pancreatic and brain cancers, SL Science aims to create cellular therapies that we believe have the potential to revolutionize the cell therapy and immuno-oncology sector within the broader biopharmaceutical industry. For more information, please visit the Company's website at: https://www.slbtgroup.com/ and follow SLBT on X, LinkedIn, FB, IG and Threads.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Offerings
Registration 333-297881
Filing attachments
slbt-20260630xex99d1.htm · 6-K · 2026-10-26
Table of Contents Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS OF SL SCIENCE HOLDING LIMITED AND SUBSIDIARIES Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025 F-2 Unaudited Interim Consolidated Statements of Operations and Comprehensive (Loss) Income for the six months ended June 30, 2026 and 2025 F-3 Unaudited Interim Consolidated Statement…
Read attachment ↗slbt-ex99d2.htm · 6-K · 2026-10-26
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS References in this report (this “Report”) to “we,” “us” or the “Company” refer to SL Science Holding Limited, a Cayman Islands exempted company, and its consolidated subsidiaries. References to our “management” or our “management team” refer to our officers and directors. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with …
Read attachment ↗tm2626021d1_ex99-1.htm · 6-K · 2026-09-24
Exhibit 99.1 The Nasdaq Stock Market, Inc. D: +852 3656 6054 Listing Qualifications E: nathan.powell@ogier.com 9600 Blackwell Road Rockville, MD 20850 United States of America ────────────────────────────────────────────────────────────────────────────── D: +852 3656 6061 E: florence.chan@ogier.com …
Read attachment ↗tm2620209d1_ex99-1.htm · 6-K · 2026-07-10
Exhibit 99.1 SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that the Company has submitted an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administra…
Read attachment ↗tm2617928d1_ex99-1.htm · 6-K · 2026-06-15
Exhibit 99.1 SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market June 12, 2026 14:51 ET | Source: SL Science Holding Limited Post-combination company, SL Science Holding Limited, to commence trading on the Nasdaq Stock Market under the ticker symbol “SLBT” Transaction provides strategic capital to advance proprietary Gamma delta T cell-based "off-the-shelf" cellular therapies for solid tumor indications, in…
Read attachment ↗